Article

Noradrenergic and dopaminergic effects of (+)-amphetamine-like stimulants in the baboon Papio anubis.

Division of Nuclear Medicine, Russell H. Morgan Department of Radiology and Radiological Science, Johns Hopkins University School of Medicine, Baltimore, Maryland 21287, USA.
Synapse (Impact Factor: 2.43). 06/2005; 56(2):94-9. DOI: 10.1002/syn.20126
Source: PubMed

ABSTRACT (+)-Amphetamine, (+/-)-ephedrine, and phentermine are commonly used appetite suppressants that release monoamines from nerve cells by acting as substrates for biogenic amine transporters. One key difference among the three drugs is their selectivity for norepinephrine (NE) release vs. dopamine (DA) release. The NE/DA selectivity ratios for these drugs as determined in vitro [(EC50 NE(-1))/(EC50 DA(-1))] are (+/-)-ephedrine (18.6) > phentermine (6.7) > (+)-amphetamine (3.5). The in vitro data suggest that when administered in vivo, these stimulants might differ in their ability to release DA from nerve terminals in the brain. To test this hypothesis, noradrenergic effects (i.e., plasma NE) and dopaminergic effects (i.e., central DA release) were assessed when each drug was administered intravenously (1.5 mg/kg) to anesthetized baboons. Central DA release was determined via positron emission tomography using the method of [11C]raclopride displacement. In the present investigation, high doses of these stimulants increased plasma NE and DA in parallel, but only (+)-amphetamine released central DA from neurons and decreased plasma prolactin. None of the drugs altered plasma amine metabolite levels, indicating no inhibition of monoamine oxidase activity at the administered doses. Plasma drug levels measured in baboons were higher than those measured in human patients taking prescribed doses of the drugs. Viewed collectively, the present data indicate that typical clinical doses of phentermine and (+/-)-ephedrine may not release central DA in humans, a hypothesis that should ultimately be tested in controlled clinical studies.

0 Bookmarks
 · 
89 Views
  • [Show abstract] [Hide abstract]
    ABSTRACT: It has been reported that the redox sensing system in the hypothalamus participates in fuel metabolism and that endogenous antioxidants contribute to the regulation of phenylpropanolamine (PPA), an anorectic drug-induced appetite suppression. We explored whether the signal transducer and activator of transcription-3 (STAT3) is involved in PPA's action. Rats were given PPA once a day for 4 days. Changes in endogenous antioxidants, Janus kinase-2 (JAK2), STAT3, neuropeptide Y (NPY), and proopiomelanocortin (POMC), levels during PPA treatment were assessed and compared. Feeding, body weight, and NPY decreased with the biggest reduction on Day 2 during PPA treatment. Antioxidants, JAK2, pSTAT3, POMC expression, and STAT3/DNA-binding activity increased and were expressed in a pattern opposite to NPY expression. Moreover, cerebral STAT3 knockdown modified PPA-induced anorexia and antioxidants, POMC, and NPY expression. superoxide dismutase immunoreactivity in the hypothalamus increased and the inhibition of hypothalamic reactive oxygen species (ROS) production reversed antioxidants, STAT3, POMC, and NPY expression. It is suggested that hypothalamic JAK2-STAT3 participates in regulating antioxidants-mediated appetite control. This result may further the understanding of ROS-involved appetite control.
    Archives of Toxicology 05/2014; · 5.08 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Obesity is a complex problem that is now considered a chronic metabolic disease. In Korea, phentermine has been widely used for the treatment of obesity in the primary care setting since 2004. However, there have been very few studies on the safety and efficacy of phentermine. To investigate the safety and efficacy of this drug, a postmarketing surveillance study was performed. A total of 795 patients with obesity (body mass index ≥ 25 kg/m(2)) were enrolled from 30 primary care centers in Korea from September 2006 to November 2007. Patients were examined to ascertain safety and efficacy at 4-, 8-, and 12-week intervals. The criterion for efficacy was defined as a weight loss ≥ 5% of body weight. Of the 795 enrolled patients, 735 (92.5%) were evaluated in safety assessments and 711 (89.4%) was included in efficacy assessments. A total of 266 adverse events (AEs) were reported by 218 patients (30.6%), and no serious AEs were reported. Among 711 patients, 324 patients (45.6%) lost ≥ 5% of their body weight. The mean weight loss was 3.8 ± 4.0 kg. AEs are commonly associated with phentermine, even though phentermine is effective for weight loss and relatively well-tolerated.
    Korean Journal of Family Medicine 09/2013; 34(5):298-306.
  • [Show abstract] [Hide abstract]
    ABSTRACT: Gas-expanded liquids have recently generated great interest, because of their distinct behaviour, which combines gas and liquid characteristics, and because they are more environmentally benign than traditional organic solvents. In this work, a methodology for the integrated design of a CO2-expanded solvent and a reactor for a Diels-Alder reaction is presented. The co-solvents studied are acetonitrile, methanol and acetone. The solvatochromic equation is used for the prediction of the rate constant combined with a preferential solvation model, while the group-contribution volume translated Peng Robinson is used for the phase equilibria. Finally, the most appropriate co-solvent and the optimum operating conditions are proposed for the particular process.